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Summary p21 (WAF1/CIP1) protein expression in various thyroid tissues, including thyroid carcinoma, was
studied by means of immunohistochemistry using anti-p21 monoclonal antibody. Normal follicles and
hyperplasias rarely expressed p21, whereas immunohistochemically positive cells were also too rarely found in
follicular adenomas to justify these cases being classified as positive. Twenty eight of the 93 carcinomas
examined (30.1%), however, were positive for p21. Of the p21-positive cases, 80% of the undifferentiated and
28.6% of the poorly differentiated carcinomas showed lesions co-expressing p21 and p53. If diffuse
immunoreactivity of p53 reflects the p53 mutation, our results indicate that p21 in these carcinomas can be
induced by p53-independent as well as by p53-dependent pathways. On the other hand, well-differentiated
carcinomas did not co-express these two proteins and it therefore remains unclear whether p53-independent or
p53-dependent pathways are predominant in this type of carcinoma. The incidence of expression of p21 was
very similar in undifferentiated (26.3%), poorly (28.0%) and well-differentiated carcinomas (32.7%), even
though they are characterised by different degrees of malignancy. Furthermore, no correlation between p21
expression and either clinical parameters or patient's prognosis could be established. These results suggest that
p21 is only marginally related to the characteristics of thyroid carcinoma and can play only an adjuvant role in
regulating the progression of this carcinoma.
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p21 is a protein encoded in the WAFI/CIPI gene on
chromosome 6p. This protein constitutes one of the cdk
inhibitors and regulates the cell cycle universally (Xiong et
al., 1993; Harper et al., 1993; El-Deiry et al., 1993).
Furthermore, it binds to the proliferating cell nuclear
antigen (PCNA) to inhibit DNA replication (Flores-Rozas
et al., 1994; Li et al., 1994). WAFI/CIPI was, at first, found
to be induced directly by wild-type p53 (El-Deiry et al., 1993)
and another report indicated that WAFI/CIPI is transcrip-
tionally activated in p53-mediated GI arrest and apoptosis
but not in p53-independent ones (El-Deiry et al., 1994). These
findings suggest that p21 is a downstream effector of p53. On
the other hand, a few studies using fibroblasts from p53
knock-out mice (Michieli et al., 1994), breast carcinoma cells
(Sheikh et al., 1994) and human leukaemia cells (Zhang et al.,
1995) have shown that p21 is inducible also in a p53-
independent manner.
Recently, studies of p21 expression in human normal and
neoplastic tissues have attempted to elucidate the manner in
which this protein effects regulation. El-Deiry et al. (1995)
reported that p21-expressing lesions in gastrointestinal tracts
were highly compartmentalised and correlated with prolifera-
tion, while such compartmentalisation was largely abrogated
in colonic neoplasms. This was the first report on
immunolocalisation of p21 and similar studies for the
pancreas and brain were published subsequently (DiGiu-
seppe et al., 1995; Jung et al., 1995). Furthermore, we
investigated p21 expression in human breast carcinoma
tissues and found that the lack of p21 expression in breast
carcinomas was related to prognostic factors, such as lymph
node metastasis and histological grade, and that it affects
even prognosis itself (Ito et al., 1996). However, carcinoma
progression is not uniform or immediate in every organ.
Thyroid carcinoma has two thoroughly polarised character-
istics of progression, depending on the pathological type.
Anaplastic (undifferentiated) carcinoma is characterised by
exceptionally quick progression with dire prognosis, while
other types show slow growth with an excellent prognosis. In
this study, we investigated p21 expression in thyroid tissues,
including thyroid carcinoma, in order to investigate whether
any features of positivity and of manner of expression of this
protein in thyroid carcinoma show any of the special
characteristics described above. We also investigated the
relation between the expressions of p21 and p53 to determine
whether p21 is induced by p53-dependent or -independent
pathways.
Materials and methods
Cell line and tissue specimens
Human breast carcinoma cell lines, MCF-7 and MDA-MB-
231, were provided by the Japanese Cancer Research
Resources Bank. Cells were cultured in RPM1 -1640
medium supplemented with 10% fetal calf serum (FCS) at
37°C in 5% carbon dioxide. Tissue specimens were obtained
between 1988 and 1995 from 93 patients undergoing
thyroidectomy for thyroid carcinoma and from 25 patients
with benign tumours [15 follicular adenomas and 10
hyperplasias (Basedow's disease)]. The carcinomas consisted
of 19 anaplastic (undifferentiated) carcinomas (UDC), 64
papillary carcinomas and 10 follicular carcinomas. Twenty-
three papillary and two follicular carcinomas were classified
as poorly differentiated (PDC) and the rest as well
differentiated (WDC) (Sakamoto et al., 1983; Carcangiu et
al., 1984; Papotti et al., 1993). Lung metastasis was detected
preoperatively in two patients with PDC and one with WDC.
The tissues were fixed overnight with 10% buffered formalin.
After being washed for over 1 h with water and dehydrated
through a graded ethanol series at 4°C, the tissues were
immersed three times (30 min each time) in xylene pools and
four times (60 min each time) in paraffin pools and then
embedded in paraffin. For Western blotting, about 1 g of
tumour tissue was stored at - 80°C after snap freezing in
liquid nitrogen.
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Antibodies
The monoclonal anti-p21 antibody was purchased from
Oncogene Science (New York, USA) and the polyclonal
anti-p53 antibody (CM-1) from Novocastra (Newcastle, UK).
These were used as primary antibodies at concentrations of
1:50 and 1:4000 respectively.
Statistical analysis
The differences in positivity of the two proteins, p21 and p53,
among the various thyroid tissues and clinicopathological
parameters were compared by chi-square analysis. P-values
of less than 0.05 were considered statistically significant.
Western blot analysis
About 2 x 106 cells were collected and lysed in 1.0 ml of lysis
buffer (10 mm disodium hydrogen phosphate, 154 mM
sodium chloride, 1% Triton X-100, 12 mM sodium deox-
ycholate, 3.5 mM sodium dodecyl sulfate (SDS), 0.2%
sodium azide, 0.95 mM sodium fluoride, 2 mM phenylmethyl-
sulphonyl fluoride (PMSF) in 1 M disodium hydrogen
phosphate, pH 7.25, 50 mg ml-' aprotinin and 50 mM
leupeptide). The lysates were clarified by centrifugation at
14 000 g for 20 min at 4°C. About 100 mg of tissues were
homogenised in 1.0 ml of lysis buffer and clarified by
centrifugation at 15 000 g for 30 min at 4°C. Total cellular
protein was determined with the Bradford protein assay
(Biorad, CA, USA) using bovine serum albumin as a
standard. Protein samples of 50 or 100 ,ug were treated with
SDS-PAGE loading buffer (at a final concentration of
65 mM Tris, 5% 2-mercaptoethanol, 3% SDS and 10%
glycerol) at 100°C for 5 min. The samples were then
separated by electrophoresis on SDS-polyacrylamide gels
(7.5%) and transferred to Immobilon polyvinylidene
difluoride (PVDF) membranes (Millipore, Bedford, MA,
USA) in a transfer buffer containing 192 mM glycine,
25 mM Tris, pH 8.3, 20% (v/v) methanol and 0.02% SDS.
After blocking with 5% skimmed milk, the membranes were
incubated with a primary antibody at a concentration of
10 ,g ml-'. The filters were then washed with TBST (Tris-
buffered saline, 50 mM Tris-HCI, pH 7.5, 150 mM sodium
chloride) plus 0.1% Tween 20 (Sigma, St Louis, MO, USA),
followed by incubation with the second antibody which had
been alkaline phosphatase-conjugated. The filters were again
washed in TBST and developed with the Proto Blot NBT and
BCIP Color Development System (Promeaga, Madison, WI,
USA).
Immunohistochemistry
Cultured cells were collected, cytocentrifuged onto poly-L-
lysine-coated glass slides, immediately fixed in buffered
formalin for 1 h, and washed in distilled water for 5 min.
Tissue sections were prepared in 4 Mm-thick slices from
paraffin-embedded thyroid tumour specimens. The paraffin
was then removed in xylene three times, after which the
tissues were rehydrated through a graded ethanol series
ranging from 100% to 60%. After quenching endogenous
peroxidase activity by immersing the sections in 0.3% (v/v)
hydrogen peroxidase containing 0.1% (w/v) sodium azide for
30 min, non-specific binding was blocked by treatment with
10% (v/v) normal rabbit serum for 30 min. The primary
antibody was applied to the slices and incubation was
performed overnight at 4°C in a moist chamber. After
washing in 0.01 mol 1-1 phosphate-buffered saline (pH 7.2)
(PBS), biotinylated anti-mouse immunogloblin (Histofine
SAB-PO kit, Nichirei, Tokyo, Japan) was applied and the
slides were incubated for 30 min at room temperature. After
a second washing in PBS, peroxidase-conjugated streptavidin
(Hiastofine SAB-PO kit) was applied and the slides were
again incubated for more than 30 min. The excess complexes
were then washed off and the immunoreactivity was
visualised by incubating the slides for 5 min in 0.05 mol 1-l
Tris-HC1 (pH 7.6) containing 0.02% (w/v) 3,3-diaminobenzi-
dine tetrahydrochloride with 0.03% (v/v) hydrogen peroxide.
Tissue sections were counterstained for 3 min in 0.5% methyl
green. A negative control for immunohistochemistry of p21
employing normal mouse serum was included in each staining
procedure.
Results
To establish the specificity of anti-p21 antibody, we
performed Western blot analysis for MCF-7 cells and
MDA-MB-231 cells employed as, respectively, positive and
negative controls (Sheikh et al., 1994). The same analysis was
used for representative cases of matched pairs of normal and
carcinoma thyroid tissues immunohistochemically positive for
p21 (Figure 1). The result showed that carcinoma tissues as
well as MCF-7 cells produced much more intense signals for
p21 at 21 kDa than did normal follicles. MDA-MB-231
demonstrated no signals for p21.
Immunohistochemical staining of MCF-7 cells, used as
positive control, demonstrated diffuse nuclear staining of p21
(Figure 2a), whereas p21-positive cells were rarely found
among MDA-MB-231 cells (Figure 2b) (Sheikh et al., 1994).
When various thyroid tissues were subjected to immunohis-
tochemical examination, p21 was rarely detectable in normal
follicles and hyperplasias. Some follicular adenoma cells were
immunoreactive for p21 but their positive cell rates in each
case were less than 10% (Figure 3a). In 30.1% of the
carcinomas, p21-immunoreactive cells were more often
observed in scattered and/or compartmentalised configura-
tions. The p21-positive cell rate was usually less than 30%
and rarely exceeded 50%. In this study, therefore, we
classified the samples as positive when more than 10% of
carcinoma cells were immunoreactive. The results for the
carcinomas are summarised in Table I. The incidence of p21-
positive case was similar for anaplastic carcinomas (26.3%)
(Figure 5a), papillary carcinomas (31.3%) (Figure 4a and Sc)
-21 kDa
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Figure 1 Western blot analysis of p21 in matched pairs of
normal and carcinoma thyroid tissue (N, normal; T, tumour).
MCF-7 cells were used as positive control (Po) and MDA-MB-
231 cells as negative control (Ne).
a b
Figure 2 Immunohistochemical staining of p21 in MCF-7 cells
(a) and MDA-MB-231 cells (b). Most MCF-7 cells are
immunoreactive for p21, whereas p21-positive cells are rarely
seen among MDA-MB-231 cells. Scale bars=200,um.p21 in thyroid carcinoma
Y Ito et al
and follicular carcinomas (30.0%) (Figure 4b). Furthermore,
p21 expression also showed very similar ratios in UDCs
(26.3%), PDCs (28.0%) and WDCs (32.7%) (Table II),
indicating that p21 positivity does not depend on carcinoma
differentiation, which is considered the most significant
prognostic factor for this carcinoma. No correlation could
be established between p21 expression and clinicopathological
parameters, such as age and sex (data not shown).
Anti-p53 polyclonal antibody, CM-1, was used in an
immunohistochemical examination of p53 in this series.
Although this antibody recognises both wild-type and
a b
mutant p53, the former is known to be undetectable or, if
detectable, can be observed only in very scattered or
compartmentalised configurations in few lesions because of
its short life (Finlay et al., 1988; Grontajaski et al., 1984).
Normal thyroid follicles and hyperplasias expressed p53 in a
highly limited fashion. Figure 3b represents the case which
showed p53 immunoreactivity with the highest positivity of
all follicular adenomas we examined, but even in this case the
positive cell ratio was still very low and much less than 10%.
All carcinoma cases classified as positive showed p53
immunoreactivity in the nuclei of the carcinoma cells very
diffusely (Figures Sb and d and 6). The results showed that
p53 overexpression was observed in 16.1% of the carcinomas
tested and a statistically significant difference (P<0.01) was
found between p53 positivity and carcinoma differentiation
(Table III). Especially noteworthy is that, among WDCs,
only one case was classified as p53 positive (Figure 6). Table
IV shows the results of immunohistochemical investigation,
using serial sections, of co-expression of p21 and p53. Four
UDCs and two PDCs, that is, 80% of the p21-positive UDCs
and 28.6% of the p21-positive PDCs, had lesions co-
expressing p21 and p53 (Figure 5). No co-expressing lesion
was observed in any of the WDCs. On the other hand, of the
p53-negative cases, one of the eight UDCs (12.5%), five of
the 16 PDCs (23.8%) and 16 of the 48 WDCs (33.3%) were
positive for p21.
The three patients, two with PDC and one with WDC,
Figure 3 Immunostaining of p21 (a) and p53 (b) in follicular
adenoma. Only a small percentage of the cells was immunor-
eactive, as indicated by arrows. Scale bars=200,um.
a b
Table I p21 Expression in thyroid carcinoma tissues (%)
Positive Negative Total
Anaplastic carcinoma 5 (26.3) 14 (73.7) 19
Papillary carcinoma 20 (31.3) 44 (68.8) 64
Follicular carcinoma 3 (30.0) 7 (70.0) 10
Total 28 (30.1) 65 (69.9) 93
d
b
Figure 4 Typical staining profiles of p21 in (a) papillary
carcinoma (PDC) and (b) follicular carcinoma (WDC). Scale
bars= 100, m.
Figure 5 A comparative immunohistochemical examination of
p21 (a, c) and p53 (b, d) in UDC (a, b) and PDC (c, d). p21-
positive carcinoma cells co-express p53 in both cases. Scale bars: a
and b = 150,um; c and d =200im.
Table II Relationship between p21 expression and differentiation of
thyroid carcinoma (%)
Positive Negative Total
Undifferentiated 5 (26.3) 14 (73.7) 19
carcinoma
Poorly differentiated 7 (28.0) 18 (72.0) 25
carcinoma
Well-differentiated 16 (32.7) 33 (67.3) 49
carcinoma
Total 28 (30.1) 65 (69.9) 93p21 in thyroid carcinoma
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whose lung metastasis had already been detected preopera-
tively, all underwent total thyroidectomy for RI therapy with
"'1I to control metastasis: p21 immunoreactivity was detected
in one PDC patient, whereas all were negative for p53.
Therefore, no apparent discrepancy was found in terms of
p21 and p53 expression between the cases with and without
lung metastasis. Finally, we also investigated the prognosis
for patients in this series, except for six PDCs and four
WDCs, who were lost track of shortly after surgery.
Although our follow-up periods (6 to 50 months) have not
been long enough to obtain meaningful results so far, all 19
patients with UDC, regardless of p21 and p53 expression,
and the only p53 immunohistochemically positive WDC
patient (Figure 6), who was negative for p21, have died as a
result of carcinoma within one year post-operatively. Of the
three patients with preoperatively detected lung metastasis,
one with PDC has died of cardiac failure unrelated to thyroid
carcinoma and the remaining two are still under treatment
for metastasis. Furthermore, two patients, one with PDC
with co-expressing lesions of p21 and p53 and another with
WDC positive for p21 only, have shown local recurrence, the
Table III Relationship between mutant p53 expression and
differentiation of thyroid carcinoma (%)
Positive Negative Total
Undifferentiated 10 (52.6) 9 (47.4) 19
carcinoma
Poorly differentiated 4 (16.0) 21 (84.0) 25
carcinoma
Well-differentiated 1 (2.0) 48 (98.0) 49
carcinoma
Total 15 (16.1) 78 (83.9) 93
P<0.01.
Figure 6 Immunostaining of p53 in WDC which was the only
case of p53 positivity in WDCs. This patient has died within one
year post-operatively. Scale bar = 100 jim.
Table IV Relationship between expressions of mutant p53 and p21
p53
+ - Total
(a) Undifferentiated carcinomas
p21+ 4 1 5
p21- 6 8 14
Total 10 9 19
(b) Poorly differentiated carcinomas
p21+ 2 5 7
p21- 2 16 18
Total 4 21 25
(c) Well-differentiated carcinomas
p21+ 0 16 16
p21- 1 32 33
Total 1 48 49
first patient 8 and the second 6 months post-operatively.
They are scheduled for reoperation. All other patients are still
alive with no symptons of recurrence so far.
Discussion
In this study, we investigated p21 expression in various
thyroid tissues. In normal follicles, only faint signals were
detected by Western blot analysis and p21 immunohisto-
chemically positive cells were rarely found. A previous report
proved that p21 can be active as a negative regulator of cell
proliferation in some normal organs (El-Deiry et al., 1995).
According to this report, lesions expressing p21 intensely
were observed selectively in unreplicative and post-replicative
compartments in the gastrointestinal tract epithelia. It is thus
suggested that the quantitative level of p21 protein in follicles
of the thyroid is definitely lower than in gastrointestinal tract
epithelia, probably because the latter can be expected to
require much higher levels of p21 expression in order to
regulate the active cell replication caused by the rapid
metabolism. The observation that, in hyperplasias, p21
levels were as low as in normal follicles seems reasonable,
for the entity of this disease is overproduction of thyroid
hormones by each cell rather than cell proliferation.
Among tumours of the thyroid, none of the follicular
adenoma tested showed high levels of p21 protein. It appears
that p21 has little clinical significance for follicular adenoma,
possibly because it is a benign disease with low proliferation
activity, which does not require restriction by p21 over-
expression. Concerning the thyroid carcinomas, p21 was
often overexpressed, probably in order to control the
abnormal cell cycle progression and cell replication of
carcinoma cells negatively. However, overexpression or lack
of expression of p21 was not related to pathological type,
carcinoma differentiation or other clinicopathological para-
meters such as age, sex and distant (lung) metastasis. These
observations suggest that only minor clinical significance can
be attributed to this protein in thyroid carcinoma, in contrast
to breast carcinoma (Ito et al., 1996). However, there is a
possibility that mutant p21 protein recognised by the
antibody we used is expressed more frequently in UDCs or
PDCs than in WDCs. Reports on WAFI/CIPI mutation are
rare (Shiohara et al., 1994; Li et al., 1995), but a study of a
larger number of UDCs and PDCs is needed to reach a
definitive conclusion as to whether p21 in thyroid carcinoma
has any clinical significance.
Our observations of p53 expression were mostly consistent
with those of previous studies (Donghi et al., 1993; Dobashi
et al., 1993; Soares et al., 1994; Holms and Nesland, 1994)
except for one (Wright et al., 1991), although their
approaches to obtaining p53 overexpression or evaluations
of p53 immunohistochemical results were different from ours.
A statistically significant (P<0.01) relationship was estab-
lished between the staining positivity of p53 and carcinoma
differentiation, indicating that p53 protein abnormalities
reflect the degree of malignancy of thyroid carcinoma and
play an important role in the progression from well-
differentiated carcinoma to poorly or undifferentiated
carcinomas, as already reported by Holms and Nesland
(1994). Furthermore, the results of our investigation into
patients' prognosis showing that the PDC patient with
recurrence was p53 positive and, especially, that the sole
p53-positive patient with WDC has died, suggest that p53
diffusely positive cases must be followed up carefully even if
they do not show severe pathological malignancy.
Concerning the co-expression ofp21 and p53, 80% of p21-
positive UDCs and 28.6% of p21-positive PDCs had lesions
co-expressing p21 and mutant p53. These findings suggest
that WAFl/CIPI transcription and p21 expression can be
regulated by some inducers other than wild-type p53 and that
p53-indepdent pathways are functional in these types of
carcinoma. However, this conclusion is based on the
hypothesis that p53 diffuse immunoreactivity reflects p53p21 in dtyr wa cxm
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mutation. This hypothesis is generally accepted but. if it is
established that p53 immunohistochemical overexpression can
result from increased indication or decreased degradation of
Wild-type p53 in UDCs and PDCs. the above conclusion may
have to be somewhat revised. On the other hand, no co-
expressing lesion was observed in any of the WDCs but we
cannot derive any definite conclusion from this observation.
Ofcourse. it is possible that p21 in WDCs is induced by wild-
type p53 through a p53-dependent pathway, but this
supposition is less than convincing, because there is no
evidence that p21 cannot be induced by anything other than
p53 in cases with wild-type p53. Furthermore. generally, p21
does not occur in high incidences in thyroid carcinoma even
when p53 is assumed to be wild, in other words.
immunohistochemicallv negative. In UDCs and in PDCs.
which apparently have p53-independent pathways, the
occurrence of p21-positive cases in p53-negative cases was
very low. 12.5% and 23.8% respectively. This indicates that
p53-dependent pathways are not very functional. even if p21
expressed in all such UDC and PDC cases were actually to be
induced by wild-type p53. Strangely enough. our results also
indicate that. even in WDCs. p21 is inducible by p53 in a
maximum of only 33.3% of the WDCs with wild-type p53. It
has been reported that p53 can mutate even in p53
immunohistochemically negative cases (Ohue et al.. 1994;
Wynford-Thomas et al.. 1992). and it could be hypothesised
that p21 might not be able to be expressed because ofWAF1
CIPI gene abnormalities: these considerations may explain
the above-mentioned unusual phenomenon to some extent.
but. to our knowledge. previous reports have proved that
neither of these two potentially explanatory phenomena
occurs very often (Ito et al.. 1992: Yoshimoto et al.. 1991:
Donghi et al.. 1993: Fagin et al.. 1993: Ohue et al.. 1994:
Shiohara et al.. 1994: Li et al.. 1995). As no studies of this
kind for other carcinomas have been published yet. it is
difficult to evaluate this figure. 33.3%. but we feel that p53 is
less active as a p21 inducer and promoter than expected in all
types of this carcinoma including WDC. The only exception
may be the medullary type. which was not investigated in the
present study.
Although our results can be interpreted in various wavs.
they generally indicate that p21 plays only an adjuvant role in
regulating the progression of thyroid carcinoma. p21 was
expressed. regardless of how it was induced. with almost
constant, but not high. incidence in UDCs. PDCs and
WDCs. although these three types of carcinomas appear to
have different degrees of malignant potential. Moreover. all
the UDC patients have died as a result of carcinoma and
most patients of other types are still alive with no symptoms
of recurrence. regardless of the positivity of p21. Therefore.
our final conclusion at present is that p21 is not significantly
related to the two basic and polarised characteristics of this
carcinoma, that is, exceptionally quick progression of the
undifferentiated type and slow growth with an excellent
prognosis for the other types. Therefore. we now hypothesise
that there must be some other negative modulators of the cell
cycle progression. for example. p16 (Serrano et al.. 1993).
which determine the differences in malignant potential and
prognosis of UDC. PDC and WDC. Furthermore. an
investigation as to whether there is any difference in p221
and p53 expression between patients exposed to nuclear
radiation and those living in a normal environment could add
valuable insights to this field of investigation.
Abbreviations
PDC. poorly differentiated carinoma; UDC. undifferentiated
carinoma; WDC. well differentiated carcinoma: cdk. c!vclin-
dependent kinase: PBS. phosphate-buffered saline (pH 7.2).
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